Evaluating the Role and Efficacy of Cobenfy (Xanomeline and Trospium Chloride) in Schizophrenia Treatment - review
Schizophrenia is a complex psychiatric disorder often resistant to dopamine-targeting antipsychotics. Cobenfy, a combination of xanomeline and trospium chloride, offers a novel approach by modulating muscarinic receptors while minimizing side effects. This review evaluates its efficacy and safety, particularly in treatment-resistant cases. Clinical trials show significant reductions in both positive and negative symptoms, positioning Cobenfy as a promising alternative.
Authors
- Agnieszka Kluz (ORCID: https://orcid.org/0009-0006-7427-5818)
- Aleksandra Pliszka (ORCID: https://orcid.org/0009-0003-5938-5929)
- Michał Mazur (ORCID: https://orcid.org/0009-0007-8157-5293)
- Zák K (ORCID: https://orcid.org/0009-0006-4036-090X)
- Katarzyna Michalak (ORCID: https://orcid.org/0009-0005-0856-1536)
- Katarzyna Madyniak (ORCID: https://orcid.org/0009-0003-6927-3832)
- Weronika Jarych
- Krystian Zukierski (ORCID: https://orcid.org/0009-0008-1428-5744)
- Hubert Jucha (ORCID: https://orcid.org/0009-0002-0182-627X)
Institutions
- Medical University of Warsaw (PL)
- University of Gdańsk (PL)
- Gdynia Maritime University (PL)
- Institute of Physical Chemistry (PL)
- University of Warsaw (PL)
Publication Details
- Journal
- Quality in Sport
- Published
- 2025-04-23
- DOI
- https://doi.org/10.12775/qs.2025.40.59815
- Primary Topic
- Biomedical Research and Pathophysiology
- Type
- article
- Field-Weighted Citation Impact
- 0.00